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Abstract:  
Conventional chemical derivatization of metabolites in biological specimens is time-consuming, 
which limits the throughput and efficiency of metabolite profiling using a gas 
chromatography/time-of-flight mass spectrometry (GC/TOFMS) platform. We report an 
ultrasonication-assisted protocol which reduces the derivatization time from hours to about 
30 min and significantly enhances the derivatization efficiency prior to a GC/TOFMS analysis. 
The protocol was evaluated using 40 compounds representing different classes of human 
metabolites, and demonstrated good analytical precision and accuracy. In comparison with the 
conventional method, the new protocol was able to increase the intensity of most of the identified 
peaks (71.0%) in the GC/TOFMS chromatograms of human serum samples. The detected 
compounds with increased intensity include most amino acids, keto-containing organic acids, 
carbonyl-containing carbohydrates, and unsaturated fatty acids. We applied this protocol in a 
metabolomic study of human serum samples obtained from 34 patients diagnosed with 
hypertension and 29 age- and gender-matched healthy subjects. Metabolite markers associated 
with hypertension, including glucosamine, D-sorbitol, 1-stearoylglycerol, and homocysteine, 
were identified and validated by statistical methods and use of reference standards. Our work 
highlights the potential of this novel approach for the large-scale metabolite profiling of samples 
generated from plant, animal, and clinical and epidemiological studies.  
 
Article: 
INTRODUCTION 
Metabonomics or metabolomics emerged following genomics, transcriptomics, and proteomics 
as an approach for capturing global biochemical alterations associated with pathophysiological 
changes [1–3]. To date, various analytical approaches, such as proton nuclear magnetic 
resonance, liquid chromatography/mass spectrometry (LC/MS), and gas chromatography/mass 
spectrometry (GC/MS), are employed to detect the variations of low molecular mass metabolites 
(less than 1,000 Da) in biological samples (e.g., urine, blood, tissue, cell, organs) [4–6]. LC/MS 
can analyze a wide range of chemical species that are not volatile and do not need chemical 
derivatization. As a result, LC/MS is best suited for the measurement of targeted metabolites that 
are not readily amenable to GC/MS analysis because of volatility issues. As one of the analytical 
approaches frequently used in metabolomic studies, GC/MS exhibits satisfactory sensitivity and 
good resolution. Together with the sample derivatization method, GC/MS can detect the volatile 
or nonvolatile compounds, or both, in various sample matrices [7, 8]. Presently, the silylation 
approach is the preferred and widely used derivatization method for GC/MS-based metabolomic 
studies of diseases such as diabetes [9], hypertension [10], and colorectal cancer [11]. Since there 
is abundant biological information on amines, amino acids, organic acids, fatty acids, 
carbohydrates, vitamins, and phospholipids in biological samples, careful consideration should 
be given to factors which could affect the measurement of the global metabolites in GC/MS 
analysis [12, 13]. One of the most important considerations for the silylation method selected is 
its applicability to various metabolites in the biological sample. Metabolites in a given biological 
specimen differ widely from each other in chemical nature and amounts; therefore, the 
derivatization conditions of different metabolites, such as silylating reagent, reagent 
concentration, reaction time, temperature, and solvents, need to be optimized to maximize the 
number of metabolites of interest detected in a metabolomic study. Another factor to be 
considered is that the derivatization treatment for most metabolites usually requires a long 
reaction time up to 20 h [11, 13]. When simultaneously used for hundreds of biological samples, 
the derivatization process of metabolite reaction can be rather time-consuming. Additionally, 
undesirable side reactions may occur if the derivatization process is too long. Thus, there are 
many challenges associated with developing a high-throughput and high-efficiency sample 
preparation method for metabolomic studies.  
 
It has been reported that derivatization reactions can be improved with auxiliary energies, such 
as microwaves or ultrasound [14, 15]. Microwaves are electromagnetic waves which may readily 
damage biological specimens [16]. Ultrasound, however, is inexpensive and safe, and the 
integrity of most biological samples remains unchanged even after a long-term exposure to an 
ultrasonic energy field. Also, cavitation occurs by the passage of ultrasonic waves through the 
solvent. The cavitation effect can slightly increase the temperature and pressure, and can 
promote effective interaction between the substrate and the derivative reagent, and consequently 
enhance chemical reactions [17]. Ultrasonic derivatization reactions have been effectively used 
for transesterification, silylation, and glycosylation [18–21]. Fiamegos et al. [22] recently 
reported a detailed protocol for the esterification of amino acids in urine with the aid of 
ultrasonic energy. However, no relevant studies have been published to date on metabolomic 
profiling using ultrasonication for the silylation reaction of the metabolites in biological 
specimens.  
 
In this study, a high-throughput and high-efficiency ultrasonic derivatization protocol for 
analyzing endogenous metabolites in serum was developed. Much effort was directed to the 
optimization of the extraction time, methoxymation, and silylation reaction prior to instrumental 
analysis. The protocol developed was evaluated using known standard compounds and human 
serum samples. A clinical metabolomic investigation was designed to test the applicability of this 
protocol for the profiling of a wide range of serum metabolites that were significantly altered in 
association with the pathological state of hypertension.  
 
 
 
 
EXPERIMENTAL 
Materials and chemicals 
Chromatographic grade methanol, acetonitrile, ethanol, and chloroform were purchased from 
Merck Chemicals (Germany). All of the chemicals, such as pyridine, methoxyamine, n-hexane, 
and N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) containing 1% trimethylchlorosilane 
(TMCS), and the reference standards used in the study were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Forty stock solutions, including solutions of amino acids, organic acids, fatty 
acids, nucleosides, carbohydrates, and cholesterols, were prepared with ultrapure water from a 
Milli-Q system (Millipore, Billerica, MA, USA) or ethanol and were stored at −20 °C. L-2-
Chlorophenylalanine at 0.3 mg mL−1 in water and heptadecanoic acid at 0.1 mg mL−1 in ethanol 
were prepared and used as internal standards (IS).  
 
Human sera 
Serum specimens from 34 patients (61 ± 13 years old, 14 male, 20 female) diagnosed with 
hypertension and from 29 healthy subjects (59 ± 11 years old, 12 male, 17 female) were provided 
by Shanghai Yangpu Center for Disease Control and Prevention. Patient participants were 
diagnosed according to the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) (established in 2003) and China’s prevention and 
cure guide of hypertension (established in 2004) [23]. This study was approved by the 
Institutional Review Board of the Shanghai Yangpu Center for Disease Control and Prevention 
and written informed consent was obtained from all participants. Patients selected had not been 
using any therapeutic drugs within the last 12 h prior to blood collection. Venous blood samples 
were collected from patients and healthy volunteers in Eppendorf tubes, after a 12-h overnight 
fasting period, using all necessary precautions to avoid contamination. The samples were then 
allowed to clot at room temperature. Sera were then separated by centrifugation at 3,000 g for 
20 min at 4 °C, and were stored in aliquots at −80 °C. All the samples were thawed at room 
temperature and vortex-mixed before use.  
 
Sample preparation 
An aliquot of 100 μL serum sample, 300 μL methanol–chloroform (3:1 v/v), and two IS, L-2-
chlorophenylalanine and heptadecanoic acid (in 10 μL of water and ethanol, respectively), were 
mixed for metabolite extraction, and then kept at −20 °C for 10 min. After centrifugation at 
12,000 g for 10 min, 300 μL supernatant was dried completely under nitrogen. Methoxyamine 
(80 μL; 15 mg mL−1 in pyridine) was added to the residue to start the methoxymation. 
Subsequently, the sample was trimethylsilylated by adding n-hexane and BSTFA (with 
1%TMCS). All samples were analyzed by gas chromatography/time-of-flight mass spectrometry 
(GC/TOFMS) in randomized order.  
 
GC/TOFMS analysis 
GC/TOFMS analysis was performed using an Agilent 6890 gas chromatograph system coupled 
with a Pegasus III time-of-flight mass spectrometer. The system utilized a DB-5MS capillary 
column coated with 5% diphenyl cross-linked with 95% dimethylpolysiloxane (30 m × 250-μm 
inner diameter, 0.25-μm film thickness; J&W Scientific, Folsom, CA, USA). A 1-μL aliquot of 
the analyte was injected in splitless mode. Helium was used as the carrier gas, the front inlet 
purge flow was 20 mL min−1, and the gas flow rate through the column was 1 mL min−1. The 
initial temperature was kept at 80 °C for 2 min, then raised to 180 °C at a rate of 10 °C min−1, 
then to 240 °C at a rate of 5 °C min−1 and finally to 290 °C at a rate of 25 °C min−1 for 9 min. 
The injection, transfer line, and ion source temperatures were 270, 220, and 260 °C, respectively. 
The energy was 70 eV in electron impact mode. The mass spectrometry data were acquired in 
full-scan mode with the m/z range of 30–550 at a rate of 20 spectra per second after a solvent 
delay of 360 s.  
 
Ultrasonication-assisted procedures 
Ultrasonicated extraction. The organic solvent (3:1 methanol–chloroform) was used for serum 
metabolite extraction. We evaluated the extraction efficiency of the ultrasonic treatment in 
comparison with the conventional vortex method. A total of 24 tests (including replicates) were 
performed with different vortex times (2 and 10 min) and different ultrasonic times (1, 2, 3, 4, 5, 
6, 10, 15, 20, and 30 min) for metabolite extraction. The ultrasonication was carried out in a KQ-
250DB ultrasonic bath (40 kHz, 350 W).  
 
Ultrasonicated methoxymation. The methoxymation under ultrasonication was carried out 
under different conditions as follows: different reaction times (2, 5, 7, 10, 15, 20, 30, 45, and 
60 min) with a high-intensity ultrasound field (ultrasonic irradiation at 40 kHz, 350 W). The 
conventional methoxymation procedure (incubation at room temperature for 90 min or 16 h) was 
used as a control [13]. Each experimental condition was repeated three times.  
 
Ultrasonicated silylation. To optimize the silylation steps, the ultrasonication temperature, time, 
irradiation power, and silylation volume were evaluated. On the basis of the orthogonal 
experimental design L27 (313), a total of 27 ultrasonication-assisted silylation experiments were 
performed. Another two conventional silylation experiments were conducted as controls. Each 
run was duplicated (Table 1).  
 
Analytical method validation 
With use of the optimized procedure, the linearity of 40 reference standards from different 
chemical classifications was investigated in the concentration range for the routine metabolic 
analysis. The linearity of the serum metabolites was also investigated. After the instrumental 
analysis by GC/TOFMS, the analytical curve was constructed by the peak-area ratio of each 
metabolite to IS versus analyte concentration. The linearity was evaluated by the correlation 
coefficient (r 2 ). According to the signal-to-noise ratio provided by the Leco ChromaTOF 
program (version 3.30, Leco, St. Joseph, MI, USA), the limit of detection (LOD) was calculated 
for the minimum concentration of each test compound with a signal to noise ratio of 3:1.  
 
The accuracy and precision of the ultrasonic method were determined by calculating the relative 
standard deviation (RSD) and the peak-area ratios of selected metabolites to IS from serum 
samples and standards tested. The intraday precision and the interday precision of the 40 
standards were assessed within 24 h and for six consecutive days, respectively. Also, the 
reproducibility was evaluated by independently preparing serum samples six times within 24 h. 
In addition, the stability of the same serum samples was evaluated in period of 72 h. The 
recovery was determined by the addition of standard compounds at three different concentrations 
to 100 μL of serum samples.  
 
 
Table 1: Orthogonal experimental design for optimizing the derivatization conditions  
Experiment Derivatization 
temperature (°C) 
Reaction 
time (min) 
Ultrasonic irradiation 
(40 kHz, 350 W) (%) 
BSTFA+1% 
TMCS (μL) 
n-Hexane 
(μL)  
N01 35 5 100 100 20 
N02 35 10 100 60 60 
N03 35 15 100 80 40 
N04 50 5 100 60 60 
N05 50 10 100 80 40 
N06 50 15 100 100 20 
N07 65 5 100 80 40 
N08 65 10 100 100 20 
N09 65 15 100 60 60 
N10 35 5 70 80 40 
N11 35 10 70 100 20 
N12 35 15 70 60 60 
N13 50 5 70 100 20 
N14 50 10 70 60 60 
N15 50 15 70 80 40 
N16 65 5 70 60 60 
N17 65 10 70 80 40 
N18 65 15 70 100 20 
N19 35 5 40 60 60 
N20 35 10 40 80 40 
N21 35 15 40 100 20 
N22 50 5 40 80 40 
N23 50 10 40 100 20 
N24 50 15 40 60 60 
N25 65 5 40 100 20 
N26 65 10 40 60 60 
N27 65 15 40 80 40 
N28a  70 15 0 80 40 
N29a  70 60 0 80 40 
BSTFA N,O-bis(trimethylsilyl)trifluoroacetamide, TMCS trimethylchlorosilane  
aConventional silylation method as control. 
 
 
Data processing and statistical analysis of GC/TOFMS 
As described in a previous study [11], the samples were analyzed by GC/TOFMS using L-2-
chlorophenylalanine as an IS for batch quality control, and heptadecanoic acid for the data 
processing of fatty acids. In addition, L-2-chlorophenylalanine and heptadecanoic acid were 
utilized to assess process variability during sample preparation and data processing. Metabolite 
identification was performed by ChromaTOF coupled with National Institute of Standards and 
Technology (NIST) spectral library databases (2005). Authentic reference standards were used to 
further validate identified metabolites.  
 
The acquired dataset in MS files from GC/TOFMS analysis was exported into NetCDF format 
by ChromaTOF. CDF files were processed using custom scripts (revised MATLAB toolbox, 
hierarchical multivariate curve resolution (H-MCR), developed by Jonsson et al. [24, 25]) in 
MATLAB 7.0 (The MathWorks) including baseline correction, denoising, smoothing, time-
window splitting, multivariate curve resolution (identification of overlap peaks), and alignment. 
The resulting three-dimensional dataset comprised sample information, peak retention time, and 
peak intensity. Some artificial peaks generated by noise, column bleed, and by-products in the 
silylation procedure were removed manually from the dataset. The resulting data were 
normalized to the area of the IS (IS peaks were removed afterward), mean-centered, and then 
treated by unit variance scaling for further statistical analysis. Principal component analysis 
(PCA), projection to latent structures (PLS), or orthogonal projection to latent structures (OPLS) 
was carried out using the SIMCA-p 12.0 software package (Umetrics, Umeå, Sweden) to 
visually display the correlation between the experimental parameters and metabolic information. 
The following statistics, based on the models, are discussed in detail throughout this article: R2X 
is the cumulative modeled variation in the X matrix; R2Y is the cumulative modeled variation in 
the Y matrix; and Q2Y is the cumulative predicted variation in the Y variable or matrix, 
according to sevenfold cross-validation. The range of these parameters is 0-1, where 1 indicates a 
perfect fit.  
 
RESULTS AND DISCUSSION 
Ultrasonication-assisted conditions 
Optimization of ultrasonication extraction time. PLS analysis enabled a practical assessment 
of metabolite extraction efficiency of different extraction times under ultrasonication. In Fig. 1, 
the PLS loading plot with three components (R2X = 0.360, R2Y = 0.838, and Q2  = 0.258; 
explained 83.8% and predicted 25.8% of the variation in the resolved peak areas) indicated the 
inner correlation structure between the metabolite intensity (peak areas) matrix X and the 
condition matrix Y. The X matrix comprises red boxes Fig. 1, which denote the ten ultrasonic 
time points in duplicates and two vortex times in duplicates. The Y matrix comprises black 
triangles in Fig. 1, denoting the areas of the resolved 570 GC/TOFMS peaks. The areas of 
resolved peaks corresponding to different extraction time points determined the distribution of 
experimental samples on the PLS loading plot. All major peaks had a significant positive effect 
when the ultrasonic extraction time was set as 3–10 min, especially at 4 min. In addition, the 
results of all duplicates at 1–10 min showed good reproducibility in the PLS loading plot. 
However, a long ultrasonic extraction time of 15–30 min resulted in decreased reproducibility. 
These results indicate that the overall extraction efficiency of the conventional vortex method at 
2 and 10 min was not as good as the ultrasonic extraction method, particularly in comparison 
with the results with an ultrasonic extraction time of 4 min. Also, it is advisable to have a 
relatively short ultrasonication time for improved extraction efficiency.  
 
We compared the identified compounds obtained from the ultrasonic method with those obtained 
from the conventional vortex method. Most of these compounds (e.g., allantoin, alanine, 
hexadecanoic acid, and fructose) positively correlated with ultrasonic extraction methods, 
whereas only a small number of metabolites (e.g., uric acid, citrate acid, and glucosamine) 
correlated with conventional vortex methods (see Fig. S1). Therefore, we believe that in 
comparison with conventional vortexing, ultrasonication significantly enhanced the metabolite 
extraction efficiency.  
 
Optimization of ultrasonicated methoxymation. The methoxymation method is performed 
prior to silylation [26] to reduce multiple-peak formation of individual sugars owing to the 
various types of structures, such as open chain or cyclic structure, and to stabilize the carbonyl 
moieties in the aldose or ketose. In this study, the peak-area of the glucose cyclic trimethylsilyl 
(TMS) derivative to the glucose methoxime/TMS derivative is considered an indicator of 
methoxymation efficiency. The lower the peak-area ratio of two different glucose forms, the 
higher the methoxymation efficiency of glucose. As shown in Fig. 2, when the peak-area ratio 
decreased with the 20–45 min reaction time, the methoxymation efficiency of the ultrasonic 
method was better than that of the conventional method, with relatively low standard deviations 
(below 0.003). However, a 60 min reaction time resulted in a high peak-area ratio. This is 
because that derivatization efficiency may be inhibited by a prolonged derivatization time. 
Accordingly, 20 min was considered as the most suitable condition for methoxymation under 
ultrasonication.  
 
 
 
Figure 1: Study of the optimal ultrasonic time for extracting the metabolites in human serum. The projection to 
latent structures (PLS) biplot shows the correlation between the variable (peak areas) and conditions (extraction 
time). Ultrasonic extraction was carried out for 1, 2, 3, 4, 5, 6, 10, 15, 20, and 30 min (labeled as numerals), 
respectively. Conventional extraction was vortexed for 2 and 10 min (labeled as Z1 and Z2), respectively. Each 
experimental condition was duplicated. The optimal condition influencing the peak areas is 4 min, which is 
positively correlated to most of the resolved peaks  
 
 
 
Figure 2: Effect of the ultrasound-enhanced methoxymation protocol and conventional methoxymation method for 
analysis of glucose in the serum sample. A1 the peak area of the glucose cyclic trimethylsilyl (TMS) derivative, A2 
the peak area of the glucose methoxime/TMS derivative. Error bars illustrate the standard deviation (n = 3). The 
ultrasonic times (columns 1–9) were 2, 5, 7, 10, 15, 20, 30, 45, and 60 min, respectively; conventional 
methoxymation times as a control (columns 10 and 11) were 1.5 and 16 h  
 
Optimization of ultrasonicated silylation. We used an orthogonal experimental design L27 
(313) to investigate the influence of different factors (ultrasonic irradiation power, ultrasonic 
time, temperature, silylation volume, and solvent volume) on the efficiencies of silylation of 
metabolites from human serum samples. A three-component PLS model was established, with 
the parameters R2X (0.459), R2Y (0.624), and Q2 (0.372), for correlating the 29 experimental 
conditions (X matrix) to the areas of 431 peaks (Y matrix). A score-loading biplot (Fig. 3a) was 
constructed to visualize the relationship between factors, variables (resolved peak areas), and 
conditions (see Table 1). It can be seen in Fig. 3a that most of the variables clustered in the 
middle, drifted slightly to the right, and thus are considered positively correlated to three of the 
five factors: ultrasonic irradiation power, ultrasonic time, and silylation volume. Compared with 
the other factors, temperature and n-hexane have less effect on the resolved peak areas, and thus 
contribute less to the extraction and silylation efficiency. Experimental conditions labeled as 
N06, N11, N13, and N08 are located close to most of the variables (Fig. 3a), suggesting that 
these four conditions affect the silylation efficiency to a greater extent than the others. In the t1-
u1 scores plot (Fig. 3b) of the PLS model, the four experimental conditions cluster in the upper-
right quadrant, which may correlate to relatively higher peak areas. Additionally, experimental 
condition N08 (two samples), located at the upper-right corner, appears to be associated with the 
maximum peak intensity.  
 
To validate the above conclusion and to further compare the new methods (N06 and N08) with 
the conventional conditions (N28 and N29), another PLS model using 145 identified metabolites 
and eight samples was generated (three components, R2X = 0.935, R2Y = 0.998, and Q2 = 0.964). 
The relative positions of the five factors in the biplot (Fig. 3c) are consistent with those of 
Fig. 3a. This confirms that the three factors (ultrasonic irradiation power, ultrasonic time, and 
silylation volume) may strongly affect the peak areas of the identified metabolites. The 
experiments with the new ultrasonic (N06 and N08) and conventional thermal (N28 and N29) 
conditions locate separately with large intergroup and small intragroup distances. Comparatively, 
N08 is positively correlated to a higher peak area of the metabolites, showing an enhancement 
for the silylation reaction. On the basis of the above results, the optimized ultrasonic condition is 
considered to be 100% irradiation amplitude (450-W power of the nominal converter), 100 μL 
BSTFA (1% TMS), 20 μL n-hexane, and 65 °C for 10 min. The short derivatization time, which 
was only 10 min, will enable a high-throughput profiling of human biological samples.  
 
In addition, the ultrasonication used in the method enhanced the derivatization efficiency, as 
evidenced by the enhanced peak intensity for most metabolites in the human serum sample, 
involving different classes of metabolites, including amino acids, organic acids, fatty acids, and 
carbohydrates. The peak intensity of 16 amino acids was increased by 8.0–92.1% (Table S1). 
About 50% of these amino acids increased their peak intensity by 14.0% or more. It is worth 
noting that some amino acids may undergo chemical conversions (e.g., glutamine converts to 
glutamic acid) during the silylation process [27]. However, our present study indicated that the 
peak intensity of glutamine increased by 92.1% with the aid of ultrasonication, suggesting that 
the chemical conversion is minimized owing to the enhanced silylation. A the levels of number 
of keto-containing organic acids (e.g., α-ketoglutaric acid, pyruvate, 3-methyl-2-oxobutyric acid,  
 
Figure 3: Results from the optimization of the ultrasonication-assisted derivatization condition (see Table 1 for 
details). a Score-loading biplot of gas chromatography/time-of-flight mass spectrometry data from the PLS model of 
serum samples shows the correlation among factors (temperature, ultrasonic irradiation power, ultrasonic time, 
silylation volume, and n-hexane; labeled as T, ui, time, BSTFA, and nh), variables (the areas of 431 resolved peaks), 
and derivatization conditions (29 experiments, 58 samples). Typical data points representing experimental 
conditions are labeled. b The PLS scores plot (t1-u1) shows a strong correlation between the various derivatization 
conditions and the areas of the resolved peaks. Each experimental condition was performed in duplicate. c Score-
loading biplot of the PLS model indicates the correlation between factors(temperature, ultrasonic irradiation power, 
ultrasonic time, silylation volume,and n-hexane; labeled as T, ui, time, BSTFA, and nh), variables (peak areas of 145 
indentified metabolites), and derivatization conditions (N06, N08, N28, and N29)  
 
 
2-oxopentanoic acid, 3-methyl-2-oxopentanoic acid, and 2-oxohexanoic acid) in serum were 
significantly elevated by 17.1–59.8%. A possible reason is that increased “local” temperature 
and pressure generated from ultrasound activation at the interface between the cavity and the 
bulk liquid, via the collapsing bubble [28], may improve the chemical transformation of unstable 
metabolites, such as the keto–enol conversion in carbonyl-containing metabolites. In addition to 
organic acids, the levels of carbonyl-containing compound, including 3-amino-2-piperidone, 
creatinine, and hypoxanthine, were found at increased intensities. Therefore, ultrasonication may 
favor the silylation of unsaturated fatty acids with one or more double bonds, such as 
palmitelaidic acid, trans-9-octadecenoic acid, 9,12-octadecadienoic acid, and eicosenoic acid.  
 
Method validation 
The discrepancy in results obtained from sera and standards is presumably due to the matrix 
effect [29]. The compositional difference between the standard compounds and human serum 
samples will be carried into TMS derivatization and subsequent gas-chromatographic separation, 
leading to discrepancies in quantitative results of metabolites obtained from the two sample 
matrices. We investigated the linearity and the correlation coefficients (r 2) of reference 
standards and serum samples with the purpose of considering the matrix effect. We used 40 
compounds representing different classes of metabolites for the validation. The r 2 for the test 
compounds in reference standards at different concentrations approached 1.0000 with the IS 
adjustment. Analogously, the r 2 for most of the test compounds in serum samples at different 
dilution levels were higher than 0.9940. Exceptions were glycine and citric acid, with poor 
correlation coefficients (Table 2). In addition, it was found in most cases that the LODs were in 
the range from 0.03 to 0.8 μM. Higher LODs were also found within the range from 1.6 to 
4.7 μM for α-ketoglutaric acid, maleic acid, histamine, glutamine, eicosanoic acid, estrone, and 
testosterone. This finding suggests that the ultrasonic derivatization method is acceptable for 
large-scale sample profiling, as evidenced by the fact that different classes of metabolites in the 
standard samples and serum samples show good linearity and sensitivities, as compared with 
previously reported methods [8, 13].  
  
The quantitative method was validated in terms of accuracy and precision (Table 3). The 
intraday and interday RSDs of the standard compounds were in the range from 3.4 to 14.6% 
(n = 6) and from 2.1 to 14.9% (n  = 6), respectively. The results of the same 40 compounds in the 
serum samples tested indicated that the derivatized samples were stable for 72 h, with RSDs of 
less than 10.0%. Reproducibility also showed acceptable results, with relatively low RSDs 
(15.3% or less) for most of the identified compounds in the six duplicate serum samples tested 
by two different operators in our laboratory. However, poor precision and reproducibility were 
observed with estrone and testosterone. Furthermore, the recoveries of three different 
concentrations of the 39 compounds ranged from 70.0 to 118.9%, with RSDs less than 15.5%, 
except for succinic acid, with recoveries ranging from 61.1 to 75.7%. These results indicate that  
Table 2: Linearity and limit of detection (LOD) of reference standards and serum metabolites  
Compound Linear range of 
standardsa (μg.mL−1)  
n  r 2b  Linear range of serum 
samplesc (v/v)  
n  r 2b  LOD 
(μM)d  
L-α-Alanine  0.25–125.0 8 0.9991 0.3–1 8 0.9991 0.03 
L-Valine  0.25–125.0 8 0.9985 0.3–1 8 0.9969 0.04 
L-Isoleucine  0.25–125.0 8 0.9996 0.3–1 8 0.9976 0.04 
L-Proline  0.25–125.0 8 0.9963 0.3–1 8 0.9987 0.04 
Glycine 0.25–125.0 8 0.9991 0.3–1 8 0.9845 0.14 
L-Serine  0.25–125.0 8 0.9975 0.3–1 8 0.9994 0.05 
L-Threonine  0.25–125.0 8 0.9964 0.3–1 8 0.9994 0.07 
L-Aspartic acid  0.25–125.0 8 0.9969 0.3–1 8 0.9975 0.3 
L-Methionine  0.25–125.0 8 0.9992 0.3–1 8 0.9985 0.1 
4-Aminobutanoic acid 0.25–125.0 8 0.9997 0.3–1 8 0.9975 0.1 
Histamine 5.0–125.0 6 0.9931 0.3–1 8 0.9988 4.7 
Glutamine 5.0–625.0 7 0.9990 0.3–1 8 0.9961 4.1 
L-Asparagine  0.25–125.0 8 0.9978 0.3–1 8 0.9992 0.2 
L-Ornithine  2.5–125.0 8 0.9997 0.3–1 8 0.9971 0.1 
L-Histidine  0.25–125.0 8 0.9963 0.3–1 8 0.9991 0.2 
L-Lysine  0.25–125.0 8 0.9984 0.3–1 8 0.9987 0.3 
L-Tyrosine  2.5–125.0 8 0.9954 0.3–1 8 0.9950 0.3 
L-Tryptophan  2.5–125.0 8 0.9943 0.3–1 8 0.9956 0.4 
Uridine 2.5–125.0 8 0.9935 0.3–1 8 0.9964 0.08 
Maleic acid 2.5–125.0 6 0.9982 0.3–1 8 0.9962 2.3 
Succinic acid 0.25–125.0 7 0.9951 0.3–1 8 0.9980 0.04 
Fumaric acid 2.5–125.0 8 0.9984 0.3–1 8 0.9956 0.1 
α-Ketoglutaric acid 2.5–125.0 8 0.9993 0.3–1 8 0.9974 1.6 
Citric acid 2.5–125.0 8 0.9964 0.3–1 8 0.9898 0.8 
Ribitol 0.25–125.0 8 0.9942 0.3–1 8 0.9972 0.1 
D-Fructose  2.5–125.0 8 0.9983 0.3–1 8 0.9991 0.1 
D-Gluconic acid  0.25–125. 8 0.9953 0.3–1 8 0.9992 0.3 
Tetradecanoic acid 2.5–125.0 8 0.9946 0.3–1 8 0.9976 0.1 
Palmitelaidic acid 0.05–12.50 8 0.9937 0.3–1 8 0.9995 0.03 
Hexadecanoic acid 0.25–125.0 8 0.9979 0.3–1 8 0.9961 0.04 
Linoleric acid 0.05–12.5 7 0.9963 0.3–1 8 0.9963 0.06 
Oleic acid 0.25–125.0 8 0.9938 0.3–1 8 0.9945 0.06 
trans-9-Octadecenoic 
acid  
0.25–125.0 8 0.9988 0.3–1 8 0.9987 0.05 
Octadecanoic acid 2.5–125.0 8 0.9964 0.3–1 8 0.9944 0.05 
Arachidonic acid 0.0512.5 7 0.9970 0.3–1 8 0.9961 0.09 
Eicosapentaenoic acid 0.05–12.5 8 0.9977 0.3–1 8 0.9954 0.04 
Eicosanoic acid 2.5–125.0 8 0.9965 0.3–1 8 0.9953 2.0 
Docosahexenoic acid 0.25–125.0 8 0.9986 0.3–1 8 0.9958 0.08 
Estrone 2.5–125.0 7 0.9942 0.3–1 8 0.9978 1.5 
Testosterone 2.5–125.0 6 0.9986 0.3–1 7 0.9959 1.3 
aReference standards for each amino acid, organic acid, nucleoside, and carbohydrate at different concentrations were diluted with water. 
Reference standards for each fatty acid and cholesterol at different concentrations were diluted with methanol.  
bCorrelation coefficients were determined at the range of concentrations listed here.  
cA series of diluted serum samples at relative concentrations of 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 (v/v, serum/serum + water) were prepared 
with the corresponding procedure.  
dThe LOD was calculated from the analysis of reference standards with a signal-to-noise ratio of 3:1. 
 
the stability, reproducibility, and recovery of most of the compounds in serum samples were 
satisfactory, with the exception of several compounds such as succinic acid, estrone, and 
testosterone. As expected, most of the test compounds were not affected by the matrix effect of 
serum under the ultrasonic derivatization. The rationale for the use of 40 test compounds in this 
study is that they covered the major classes of metabolites, including amino acids, organic acids, 
fatty acids, nucleosides, carbohydrates, and cholesterols, exhibiting great diversity in molecular 
weight, polarity, and metabolic pathways involved. Thus, we conclude that the proposed 
ultrasonic method is stable and reliable for quantitative measurement of a wide array of 
metabolites with various chemical characteristics, and can be used for the metabolomic analysis 
of biological samples.  
 
Table 3: Precision, reproducibility, stability, and recovery of the test compounds  
Compound Intraday 
precisiona  
Interday 
precisiona  
Reproducibility Stability Recovery (%) n = 3  
RSD (%) RSD (%) RSD (%) RSD (%) 1
b   2
c   3 
d  
n = 6  n = 6  n = 6  n = 6  Average RSD  Average RSD  Average RSD 
L-α-Alanine  7.1 5.1 6.8 4.4 96.1 7.6  113.4 10.9  118.9 5.5 
L-Valine  7.0 5.4 8.6 4.9 93.0 15.3  93.5 1.1  94.2 5.3 
L-Isoleucine  6.4 6.0 8.1 4.9 80.1 7.9  86.3 1.8  92.5 2.1 
L-Proline  6.7 5.4 4.8 1.5 96.3 8.1  115.8 8.7  110.9 11.7 
Glycine 4.6 11.7 13.1 1.1 114.9 0.6  133.7 8.5  118.9 2.4 
L-Serine  6.1 5.8 2.0 1.5 82.6 5.7  86.2 7.2  89.9 9.1 
L-Threonine  5.0 4.7 1.8 1.2 91.7 14.3  91.1 7.8  93.8 6.6 
L-Aspartic acid  4.5 6.7 4.7 3.2 74.6 2.4  72.4 7.9  82.9 6.3 
L-Methionine  4.8 9.0 9.1 4.7 88.6 8.0  97.5 2.20  101.3 6.8 
4-Aminobutanoic 
acid 
4.7 9.5 1.2 0.6 70.0 12.8  79.1 3.4  92.2 1.5 
Histamine 4.1 9.2 11.1 6.9 96.9 6.3  76.2 6.6  77.2 4.7 
Glutamine 10.1 14.5 4.1 2.1 92.9 7.6  113.6 9.0  83.7 11.9 
L-Asparagine  4.1 2.5 3.8 0.4 72.3 6.1  70.2 10.4  75.8 7.0 
L-Ornithine  3.4 10.0 7.3 6.6 74.8 13.5  78.4 3.1  85.3 5.9 
L-Histidine  5.2 5.1 6.4 3.8 99.1 7.2  92.4 2.74  91.6 6.4 
L-Lysine  3.8 7.1 10.9 3.4 109.1 10.4  114.9 14.6  102.8 10.2 
L-Tyrosine  5.9 2.5 4.6 1.7 77.3 7.7  82.7 12.0  88.1 7.6 
L-Tryptophan  4.7 7.4 2.0 2.1 101.4 11.1  103.0 7.4  100.2 7.9 
Uridine 11.3 13.2 5.1 4.1 98.2 5.8  102.1 5.6  102.6 4.7 
Maleic acid 8.9 6.0 15.3 3.1 76.7 4.3  81.0 5.7  74.3 7.2 
Succinic acid 5.2 3.9 2.6 2.6 66.2 10.4  61.1 5.7  75.7 7.4 
Fumaric acid 7.3 11.9 13.6 7.1 92.7 3.3  96.1 5.5  89.4 7.3 
α-Ketoglutaric 
acid 
4.0 12.1 5.3 1.6 85.9 1.22  109.9 6.9  108.1 4.3 
Citric acid 9.1 7.6 1.7 2.4 92.1 12.8  76.8 4.7  86.2 5.5 
Ribitol 6.3 4.4 1.8 0.4 97.3 6.7  92.9 4.2  97.5 3.8 
D-Fructose  12.6 7.0 3.1 2.1 114.1 8.4  106.2 5.0  86.0 15.5 
D-Gluconic acid  14.0 9.9 5.7 1.7 112.0 4.8  113.9 1.0  115.5 1.6 
Tetradecanoic acid 11.9 2.1 2.4 0.2 105.4 14.2  117.0 4.8  117.9 2.9 
Palmitelaidic acid 10.7 4.3 0.6 0.4 82.8 4.1  89.3 1.3  92.2 3.6 
Hexadecanoic acid 10.3 3.0 2.0 3.0 114.3 8.50  118.0 0.5  118.5 0.8 
Linoleric acid 10.3 6.0 2.9 2.7 96.9 1.9  101.4 0.9  98.0 3.5 
Oleic acid 9.8 5.2 1.4 0.1 100.1 2.9  102.6 1.2  100.9 3.7 
trans-9-
Octadecenoic acid  
9.8 5.7 1.3 1.0 90.4 1.5  96.1 0.8  99.2 2.7 
Octadecanoic acid 9.4 5.2 3.2 2.2 104.1 3.7  115.4 2.3  116.5 0.5 
Arachidonic acid 10.3 5.7 2.6 2.3 97.4 6.8  96.4 1.4  99.9 2.2 
Eicosapentaenoic 
acid 
9.7 6.1 0.8 0.7 85.0 3.1  93.7 0.5  95.0 1.9 
Eicosanoic acid 14.6 14.9 4.8 5.8 104.5 1.9  92.8 2.2  97.4 2.1 
Docosahexenoic 
acid 
10.2 7.9 0.9 0.7 98.1 5.5  98.3 1.2  99.0 5.1 
Estrone 23.3 18.8 4.9 11.1 108.3 1.15  107.5 11.5  109.5 3.3 
Testosterone 16.3 9.0 5.8 23.4 82.5 11.3  88.6 5.2  91.9 5.2 
aThe intraday precision and interday precision of the test standard for each amino acid, organic acid, and carbohydrate (9.37 μg mL−1) and for each fatty acid and cholesterol 
(18.75 μg mL−1).  
bRecovery of a low concentration of the added test standard (6.25 μg mL−1) in the serum sample  
cRecovery of a middle concentration of the added test standard (12.50 μg mL−1) in the serum sample  
dRecovery of a high concentration of the added test standard (18.75 μg mL−1) in the serum sample  
 
Comparison between the ultrasonic and conventional methods for serum samples 
To evaluate the ultrasonic derivatization, serum samples obtained from ten healthy individuals 
were prepared with the ultrasonic and conventional methods respectively and the GC/TOFMS 
data obtained were processed using the H-MCR method. Although some metabolites were 
qualitatively confirmed in previous publications [8, 13], the current method identified more kinds 
of metabolites. After the matrix interference (e.g., false peak, silicone bleeding) had been 
eliminated, 145 metabolites from the resolved peaks detected in the total ion chromatograms of 
serum samples prepared by the ultrasonic method were annotated using reference standards and 
the NIST spectral library (see Table S2).  
 
Additionally, the ultrasonication-aided derivatization of human serum metabolites yielded about 
the same number of original peaks as the conventional method (663 vs. 656), but with higher 
intensity of 64.0% of the peaks, suggesting the improved derivatization efficiency with 
ultrasonication. Among the 145 identified peaks, 71.0% peaks were found with significantly 
increased intensity, among which 5.5% increased by 3 times or more, 2.8% increased by 2–3 
times, 29.0% increased by 1.2–2 times, and 33.8% increased by 1–1.2 times. About 26.2% of the 
145 peaks were found with slightly decreased intensity, and only 2.8% were found with a 
maximum decreased rate of less than 4 times (Fig. 4). Also, the ultrasonic method has an effect 
similar to that of the conventional derivatization method on the formation of methoxime, as 
evidenced by the similar mean peak-area ratio of the glucose cyclic TMS derivative to the 
glucose methoxime/TMS derivative obtained from the two methods (data not shown).  
 
 
 
Figure 4: A pie chart for the ratio of the components with the peak intensity increased and decreased in the 
ultrasonic derivatization compared with the conventional derivatization. The comparison ratio was calculated with 
the equation R (ratio) = A%/B%, in which A% represents the mean peak-area ratio of each component to the internal 
standard (IS) in serum samples prepared by the ultrasonic method and B% represents the mean peak-area ratio of 
each component to the IS in serum samples prepared by the conventional method  
 
 
Importantly, the ultrasonication-aided derivatization process involving methoxymation and 
silylation was completed within approximately 30 min. Compared with the 3 h methoxymation 
and 17 h silylation in the conventional method [11, 13], the new approach allowed a much faster 
process, which is particularly attractive for high-throughput metabolomic studies.  
 
Application 
An epidemiological study showed that hypertension is the primary risk factor for cardiovascular 
disease worldwide [30]. Metabolomics has shown great potential in advancing our understanding 
of the pathophysiological processes of hypertension in rat models [10, 31–34]. However, there 
are very few publications directly related to the global metabolic profiling of human blood, 
except for two that investigated the relationship between blood lipids and blood pressure [35, 
36]. We applied the new ultrasonic derivatization technology to analyze serum samples obtained 
from 34 elderly hypertensive patients and 29 healthy individuals. There were no significant 
differences between the two groups in age, body mass index, and gender. The typical total ion 
chromatograms of serum samples showed some obvious differences between the two groups (see 
Fig. S2).  
 
The unsupervised PCA model illustrated the clear separation between 34 hypertensive patients 
and 29 healthy counterparts (data not shown). Additionally, the metabolic profiles of the two 
groups were differentiated by an OPLS model (see Fig. S3). The two clusters of samples showed 
distinct separation from each other in the OPLS scores plot. The variance explained by the first 
and second components of the model are 21% and 19% for X (the MS data), and 69% and 22% 
for Y (the class variable), respectively, whereas the cumulative Q2 of the model is 87%. These 
results demonstrated that the multivariate statistical model is robust, with reliable predictability. 
A univariate analysis of the t test experiments was concurrently performed for the validation of 
the variable selection by the PCA and OPLS models. On the basis of the variable importance in 
the projection (VIP) values (VIP > 1.0) in the OPLS and the p values (p < 0.05) in the t tests for 
all metabolites, 38 metabolite markers were selected, including carbohydrates, lipids, amino 
acids, and amino ketones, in the hypertensive patients relative to the healthy controls (Table 4). 
Deregulations of purine metabolism, metabolism of free fatty acids, glucose metabolism, urea 
cycle, and metabolism of amino acids potentially associated with the hypertension condition 
were revealed.  
 
As one of independent risk factors for hypertension [37], the levels of serum free fatty acids were 
found to be significantly elevated in the hypertensive patients compared with the healthy 
controls. Mot fatty acids are stored as triglycerides in adipose tissue and are partially released 
into the blood pool. The degradation of glycerides is inhibited by the suppression of lipase 
release, regulating the release of fatty acid into the blood. Since the patients with metabolic 
syndrome including hypertensive conditions are closely associated with declined insulin 
response, the impaired insulin regulation in catabolism of triglycerides may result in the increase 
in the levels of serum fatty acids in the hypertensive patients [38]. In our study, the level of 1-
stearoylglycerol, 1-palmitoylglycerol, and free fatty acids (e.g., oleic acid, eicosanoic acid, 
hexanoic acid, heptanoic acid, nonanoic acid) were significantly higher in the hypertensive 
patients compared with the healthy controls. Triglycerides were also found at higher levels in the 
hypertensive patients by an enzymatic assay. Interestingly, medium-chain fatty acids (such as 
hexanoic acid, heptanoic acid, and nonanoic acid) were observed at higher levels in serum. As 
far as we know, the higher serum levels of medium-chain fatty acids and monoglycerides in 
hypertensive patients has not been reported so far. A somewhat relevant publication reported that 
administration of medium-chain fatty acids/medium-chain triglycerides (C6–C12) does not seem 
to affect blood pressure, but is helpful to improve cardiac dysfunction [39]. Besides the elevated 
level of glucose confirmed by our study and previous reports, we detected changes of other 
monosaccharides and disaccharides in patients (Table 3), among which the levels of galactose, 
glucosamine, sorbose, sucrose, sorbitol, inosose, and myo-inositol were elevated, whereas those 
of fructose, cellobiose, and lactobionic acid were decreased. These results suggest that a 
dysregulated carbohydrate metabolism occurred in hypertensive patients, as evidenced by 
clinical observations that the development of hypertension is frequently accompanied by an 
increasing incidence of impaired glucose tolerance [40]. Uric acid, an independent predictor of 
hypertension used in the clinic [41], can be metabolized to allantoin and urea via purine 
metabolism. In our study, serum allantoin and urea were observed at higher levels in the patients, 
suggesting an upregulated urea cycle, which is consistent with the uric acid assay in the clinic . 
Table 4: Significant metabolites identified from orthogonal projection to latent structures 
discriminant analysis modeling of the metabolic profiles of hypertensive patients and healthy 
control subjects  
Metabolites VIPa  FCb  P (t test)c  
D-Fructose  2.3 0.3 4.5 × 10−18  
D-Glucose  2.2 3.0 4.3 × 10−15  
D-Galactose  2.0 2.4 6.0 × 10−8  
Glucosamine 1.6 3.8 1.2 × 10−8  
L-Sorbose  1.6 2.9 6.3 × 10−6  
Sucrose 1.3 1.8 7.3 × 10−5  
D-Cellobiose  1.3 0.4 4.8 × 10−5  
D-Sorbitol  1.2 2.6 4.6 × 10−3  
Inosose 1.1 1.9 1.6 × 10−3  
Lactobionic acid 1.1 0.5 4.7 × 10−4  
myo-Inositol  1.0 1.3 1.5 × 10−3  
Glycerol 3-phosphate 2.1 0.5 4.6 × 10−13  
Heptanoic acid 2.0 1.6 6.4 × 10−7  
1-Stearoylglycerol 1.6 4.3 2.5 × 10−7  
Oleic acid 1.5 1.4 1.7 × 10−9  
1-Palmitoylglycerol 1.4 1.5 2.6 × 10−7  
Nonanoic acid 1.3 1.3 1.2 × 10−2  
Eicosanoic acid 1.2 1.3 3.3 × 10−4  
Hexanoic acid 1.0 2.0 7.4 × 10−3  
Pipecolic acid 1.8 1.6 1.5 × 10−5  
L-Ornithine  1.8 1.5 2.6 × 10−6  
L-Lysine  1.8 1.5 1.0 × 10−5  
Pyroglutamic acid 1.5 1.3 2.4 × 10−3  
L-Histidine  1.5 1.4 2.3 × 10−4  
L-Alanine  1.4 1.2 9.5 × 10−3  
Glutamine 1.4 1.4 3.7 × 10−3  
L-Isoleucine  1.4 1.2 1.8 × 10−2  
α-Aminoadipic acid 1.3 1.7 6.5 × 10−3  
N-Acetylglycine  1.3 1.8 2.0 × 10−3  
L-Tyrosine  1.2 1.5 5.3 × 10−3  
Homocysteine 1.2 1.3 1.9 × 10−2  
L-Aspartic acid  1.2 1.6 1.6 × 10−2  
Glutamic acid 1.1 1.4 3.7 × 10−2  
L-Tryptophan  1.0 1.3 1.5 × 10−3  
Allantoin 2.0 1.5 1.3 × 10−5  
3-Amino-2-piperidone 1.7 1.5 4.5 × 10−5  
Urea 1.3 1.5 4.9 × 10−3  
2-Ketoglutaric acid 1.7 2.1 2.7 × 10−5  
Fasting blood glucosed    1.1 4.9 × 10−3  
Triglyceridese    1.5 5.5 × 10−3  
aVariable importance in the projection (VIP) is the relative influence of each metabolite on the grouping; metabolites with higher VIP values are 
more influential.  
bFold change (FC) is the ratio of the mean value for measured serum samples obtained from the hypertensive patient group to the mean value for 
the control samples obtained from the healthy subject group.  
c P was calculated with Student’s t test. P < 0.05 means statistical significance.  
dFasting blood glucose was determined using a conventional glucose oxidase - peroxidase method.  
eTriglycerides were determined by enzymatic assay. 
 
evaluation of hypertension. Homocysteine is regarded as an independent risk factor for heart 
disease in older adults [42]. Our observation of the elevated homocysteine level in elderly 
hypertensive patients is consistent with previous reports [43]. The other amino acids, such as 
isoleucine, alanine, and lysine, were also observed at higher expression levels in serum. The 
higher serum amino acid concentrations may be indicative of the disturbed nitrogen metabolism 
in hypertensive patients, which may, in turn, accelerate the urea cycle. The accelerated urea cycle 
was indicated by elevated allantoin and urea levels in serum, and was further confirmed by the 
increased level of other intermediates in the urea cycle such as aspartic acid, glutamine, and 
ornithine. As hypertension will apparently increase the burden of the blood vessels and 
glomerular filtrations in the kidney, the increased serum urea level may also correlate with 
impaired renal function, which coincides with the increased prevalence of renal disease in elderly 
hypertensive patients [44]. Therefore, we reasonably inferred that the proposed GC/TOFMS-
based metabolic profiling technology is able to characterize the metabolic disturbances 
associated with hypertension.  
 
CONCLUSION 
In this study, a novel ultrasonication-assisted extraction and derivatization protocol was 
developed for GC/TOFMS-based high-throughput metabolite profiling. The protocol was 
optimized with parameters including 4 min for ultrasonic extraction, 20 min for ultrasonic 
methoxymation, 100% irradiation amplitude (40 kHz; 350 W power), 100 μL BSTFA (1% 
TMS), and 65 °C for 10 min for ultrasonic silylation. Compared with the methods conventionally 
used for derivatization, the ultrasonic protocol significantly enhanced the derivatization 
efficiency of the detected metabolites in serum and drastically shortened the reaction time from 
hours to minutes. This is of considerable benefit for the high-throughput profiling of metabolites 
from different sample matrices. Finally, the successful utilization of this protocol in the analysis 
of serum samples from hypertensive patients highlights its potential for large-scale clinical and 
epidemiological metabolomic applications.  
 
ABBREVIATIONS  
BSTFA  N,O-bis(trimethylsilyl)trifluoroacetamide  
GC/MS  Gas chromatography/mass spectrometry 
GC/TOFMS  Gas chromatography/time-of-flight mass spectrometry 
H-MCR  Hierarchical multivariate curve resolution 
IS   Internal standard 
LC/MS  Liquid chromatography/mass spectrometry 
LOD   Limit of detection 
OPLS   Orthogonal projection to latent structures 
PCA   Principal component analysis 
PLS   Projection to latent structures 
RSD   Relative standard deviation 
TMCS  Trimethylchlorosilane 
TMS   Trimethylsilyl 
VIP   Variable importance in the projection 
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